Before Tomorrow's Earnings, Harmony's 45% Upside Call Turns on One Question: Is the Buy Signal Real?

Mizuho's upgrade raises the bar for Harmony's August 4 report

Harmony Biosciences looks more compelling only if tomorrow confirms that WAKIX is still accelerating. The catalyst is immediate: the company will report second quarter 2026 financial results on Tuesday, August 4, 2026. Investors are already looking for momentum. FactSet shows an average rating of overweight and mean price target of $45.50. Mizuho also kept its bullish stance, maintaining a Buy rating with a $51 price target, raised from $50. Near a $28 share price, that target implies roughly 45% upside. The setup is clear: bullish external optics, a higher target, and one earnings release that could either reinforce the story or expose its main vulnerability.

The core debate is durability. WAKIX revenue grew 17% to $215.4 million in Q1 2026 and then approximately $261 million in Q2, up 30% year over year. That gives the bull case real operating evidence. But Harmony is still largely a one-drug commercial story, so the market will be watching whether demand stays strong enough to support the company's full-year target. If management backs that view on August 4, the bullish case gains credibility. If it does not, the stock may struggle to hold its current narrative.

WAKIX growth is strong, but the quarter has to reinforce the trend

The bull case now depends less on whether WAKIX is selling well and more on whether the growth slope is still steepening. Preliminary Q2 WAKIX revenue of approximately $261 million followed Q1 revenue of $215.4 million, which points to meaningful quarter-over-quarter momentum on top of year-over-year growth. If the full report confirms that trend, investors have a stronger case for treating Harmony as more than a static franchise.

That matters because strong growth can do more than support a higher multiple. It can also make the company's full-year outlook look more achievable. Management has already reiterated 2026 net revenue guidance of $1.0 billion to $1.04 billion. The question for August 4 is whether that guide still fits the latest run rate, or whether investors will start to worry that the ramp is flattening just as expectations remain elevated.

IP protection and pipeline breadth matter only if they extend the WAKIX window

A fast sales quarter matters more if Harmony can extend the commercial window around it. The company has emphasized vigorously protecting WAKIX intellectual property into the 2030s and has sued AET Pharma/Sandoz over alleged infringement of an amorphous pitolisant patent. It is also exploring broader CNS indications for a recently acquired novel amorphous form of pitolisant.

That matters because it gives the pipeline a more supportive role. Strong WAKIX demand shows the commercial engine works today; IP actions aim to protect that cash flow for longer; and the broader pipeline offers a path to future value rather than serving as the main investment thesis right now. Harmony also says it has five ongoing Phase 3 registrational trials in five distinct CNS indications. If management can connect franchise protection and pipeline progress in a coherent way, a strong quarter can look like business building rather than just a one-off sales beat.

What to watch in the August 4 release and call

Investors should focus on a short list of items in the August 4, 2026 before-the-open report and accompanying call:

• Whether Q2 results confirm the Q1-to-Q2 acceleration already suggested by preliminary data.
• Whether management still expects to deliver 2026 net revenue guidance of $1.0 billion to $1.04 billion.
• How management frames patent enforcement and the broader pitolisant program.
• Whether the company still points to five ongoing Phase 3 registrational trials in five distinct CNS indications without sounding spread thin.

If those points align, the buy signal strengthens. If they wobble, the story looks more like a trade than a durable compounding setup.

Consensus optimism is clear, but execution is the cleaner signal

One analyst action or a crowded rating profile can help sentiment, but it does not prove internal alignment. Still, the external view is clearly constructive: 77% recommend buying, the consensus rating is Buy across 13 analysts, and the consensus target implies 70% upside.

The cleaner evidence is operational. Harmony has already said WAKIX Q2 revenue reached approximately $261 million, a new quarterly revenue record, and it has reaffirmed 2026 net product revenue guidance of $1.0 billion to $1.04 billion. That is the strongest visible sign of management confidence ahead of the full report. The real confirmation, though, will come from how firmly that message holds once investors get the complete quarter.

Positioning after the call

The company reports before the open on August 4 and hosts its call at 8:30 a.m. ET. After that, the setup should be judged more on execution than on analyst optimism.

• Stronger buy case: sales and guidance remain solid, and management presents IP, pipeline, and commercial momentum as complementary parts of the same plan.
• Neutral case: results are acceptable, but management sounds defensive or vague on the questions above.
• Weaker case: any sign that growth is flattening while expectations stay high.

The bullish view does not need more price targets. It needs one report that shows WAKIX momentum is still real, durable, and being backed by coherent execution.